Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
24 05 2022
Historique:
received: 13 10 2021
accepted: 17 12 2021
pubmed: 19 1 2022
medline: 21 5 2022
entrez: 18 1 2022
Statut: ppublish

Résumé

SF3B1K700E is the most frequent mutation in myelodysplastic syndrome (MDS), but the mechanisms by which it drives MDS pathogenesis remain unclear. We derived a panel of 18 genetically matched SF3B1K700E- and SF3B1WT-induced pluripotent stem cell (iPSC) lines from patients with MDS with ring sideroblasts (MDS-RS) harboring isolated SF3B1K700E mutations and performed RNA and ATAC sequencing in purified CD34+/CD45+ hematopoietic stem/progenitor cells (HSPCs) derived from them. We developed a novel computational framework integrating splicing with transcript usage and gene expression analyses and derived a SF3B1K700E splicing signature consisting of 59 splicing events linked to 34 genes, which associates with the SF3B1 mutational status of primary MDS patient cells. The chromatin landscape of SF3B1K700E HSPCs showed increased priming toward the megakaryocyte- erythroid lineage. Transcription factor motifs enriched in chromatin regions more accessible in SF3B1K700E cells included, unexpectedly, motifs of the TEA domain (TEAD) transcription factor family. TEAD expression and transcriptional activity were upregulated in SF3B1-mutant iPSC-HSPCs, in support of a Hippo pathway-independent role of TEAD as a potential novel transcriptional regulator of SF3B1K700E cells. This study provides a comprehensive characterization of the transcriptional and chromatin landscape of SF3B1K700E HSPCs and nominates novel mis-spliced genes and transcriptional programs with putative roles in MDS-RS disease biology.

Identifiants

pubmed: 35042235
pii: 483554
doi: 10.1182/bloodadvances.2021006325
pmc: PMC9131920
doi:

Substances chimiques

Chromatin 0
Phosphoproteins 0
RNA Splicing Factors 0
SF3B1 protein, human 0
Transcription Factors 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2992-3005

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA225231
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL137219
Pays : United States

Informations de copyright

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Cell Stem Cell. 2017 Mar 2;20(3):315-328.e7
pubmed: 28215825
Cell Rep. 2018 Oct 30;25(5):1304-1317.e5
pubmed: 30380420
Genome Biol. 2014;15(12):550
pubmed: 25516281
Blood. 2017 Mar 9;129(10):1260-1269
pubmed: 27940478
Cell Stem Cell. 2021 Jun 3;28(6):1074-1089.e7
pubmed: 33571445
Leukemia. 2014 Feb;28(2):241-7
pubmed: 24220272
Blood. 2013 Nov 21;122(22):3616-27; quiz 3699
pubmed: 24030381
Curr Opin Oncol. 2015 Nov;27(6):551-9
pubmed: 26352542
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Nat Rev Cancer. 2013 Apr;13(4):246-57
pubmed: 23467301
Leuk Res. 1999 Apr;23(4):385-94
pubmed: 10229325
Cancer Cell. 2016 Sep 12;30(3):404-417
pubmed: 27622333
Stem Cell Reports. 2018 May 8;10(5):1610-1624
pubmed: 29681544
Nature. 2019 Oct;574(7778):432-436
pubmed: 31597964
N Engl J Med. 2020 Oct 1;383(14):1358-1374
pubmed: 32997910
Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):15377-82
pubmed: 24003148
Nucleic Acids Res. 2016 Jul 8;44(W1):W160-5
pubmed: 27079975
Leukemia. 2016 Dec;30(12):2322-2331
pubmed: 27211273
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2850-5
pubmed: 15708978
Nat Commun. 2018 Sep 7;9(1):3649
pubmed: 30194306
Exp Hematol. 2019 Mar;71:77-84
pubmed: 30481543
N Engl J Med. 2011 Oct 13;365(15):1384-95
pubmed: 21995386
Cancer. 2021 Oct 1;127(19):3552-3565
pubmed: 34161603
Cell Rep. 2015 Nov 3;13(5):1033-45
pubmed: 26565915
Nat Genet. 2016 Oct;48(10):1193-203
pubmed: 27526324
Blood. 2020 Jul 9;136(2):157-170
pubmed: 32347921
Genome Biol. 2017 Aug 7;18(1):151
pubmed: 28784146
Blood. 2019 Jul 11;134(2):186-198
pubmed: 31010849
F1000Res. 2015 Dec 30;4:1521
pubmed: 26925227
Nat Methods. 2013 Dec;10(12):1213-8
pubmed: 24097267
Nature. 2011 Sep 11;478(7367):64-9
pubmed: 21909114
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Cell Rep. 2020 Jun 2;31(9):107688
pubmed: 32492433
Blood. 2018 Sep 20;132(12):1225-1240
pubmed: 29930011
Nat Rev Mol Cell Biol. 2014 Feb;15(2):108-21
pubmed: 24452469
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Sci Transl Med. 2019 Jul 10;11(500):
pubmed: 31292266
Annu Rev Biochem. 2019 Jun 20;88:577-604
pubmed: 30566373
Nat Med. 2020 Oct;26(10):1549-1556
pubmed: 32747829
Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5593-601
pubmed: 25480548
Nat Biotechnol. 2015 Jun;33(6):646-55
pubmed: 25798938
Leukemia. 2013 Apr;27(4):889-896
pubmed: 23070040
Dis Model Mech. 2019 Jun 4;12(6):
pubmed: 31171568

Auteurs

Georgios Asimomitis (G)

Computational Oncology Service, Department of Epidemiology & Biostatistics, and.
Center for Hematologic Malignancies, Memorial Sloan-Kettering Cancer Center, New York, NY.
Biomedical Systems Laboratory, School of Mechanical Engineering, National Technical University of Athens, Athens, Greece.

André G Deslauriers (AG)

Computational Oncology Service, Department of Epidemiology & Biostatistics, and.
Center for Hematologic Malignancies, Memorial Sloan-Kettering Cancer Center, New York, NY.
Department of Oncological Sciences.
Tisch Cancer Institute.
Black Family Stem Cell Institute, and.
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

Andriana G Kotini (AG)

Department of Oncological Sciences.
Tisch Cancer Institute.
Black Family Stem Cell Institute, and.
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

Elsa Bernard (E)

Computational Oncology Service, Department of Epidemiology & Biostatistics, and.
Center for Hematologic Malignancies, Memorial Sloan-Kettering Cancer Center, New York, NY.

Davide Esposito (D)

Department of Oncological Sciences.
Tisch Cancer Institute.
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

Malgorzata Olszewska (M)

Department of Oncological Sciences.
Tisch Cancer Institute.
Black Family Stem Cell Institute, and.
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

Nikolaos Spyrou (N)

Department of Oncological Sciences.
Tisch Cancer Institute.
Black Family Stem Cell Institute, and.
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

Juan Arango Ossa (J)

Computational Oncology Service, Department of Epidemiology & Biostatistics, and.
Center for Hematologic Malignancies, Memorial Sloan-Kettering Cancer Center, New York, NY.

Teresa Mortera-Blanco (T)

Center for Hematology and Regenerative Medicine, Karolinska Institute, Department of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden.

Richard Koche (R)

Center for Epigenetics Research, Memorial Sloan-Kettering Cancer Center, New York, NY.

Yasuhito Nannya (Y)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Luca Malcovati (L)

Unit of Precisione Hematology Oncology, Istituto di Ricovero e Cura a Carattere Scientifico S. Matteo Hospital Foundation, Pavia, Italy; and.
Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Seishi Ogawa (S)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.

Mario Cazzola (M)

Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Stuart A Aaronson (SA)

Department of Oncological Sciences.
Tisch Cancer Institute.
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

Eva Hellström-Lindberg (E)

Center for Hematology and Regenerative Medicine, Karolinska Institute, Department of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden.

Elli Papaemmanuil (E)

Computational Oncology Service, Department of Epidemiology & Biostatistics, and.
Center for Hematologic Malignancies, Memorial Sloan-Kettering Cancer Center, New York, NY.

Eirini P Papapetrou (EP)

Department of Oncological Sciences.
Tisch Cancer Institute.
Black Family Stem Cell Institute, and.
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH